Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical trial of pirotinib for the treatment of cancer in China

Trial Profile

Clinical trial of pirotinib for the treatment of cancer in China

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Mar 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pirotinib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 29 Mar 2016 Status changed from not yet recruiting to recruiting, as reported in a Sihuan Pharmaceutical Holdings media release.
    • 18 Nov 2013 New trial record
    • 10 Oct 2013 Clinical trial approval of pirotinib was accepted by the China Food and Drug Administration (CFDA), according to a Sihuan Pharmaceutical Holdings Group media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top